Thursday, July 3, 2025 7/3/2025

Develop a novel red blood cell-based microfluidic approach to assess and diagnose ME/CFS

Award Number: R21AI175960
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2023
PERIOD OF PERFORMANCE END DATE: 10/31/2025

Group Awards By:

View Award Description

Develop a novel red blood cell-based microfluidic approach to assess and diagnose ME/CFS - Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, debilitating disease with inconclusive causes and no laboratory-based diagnostic tests. Oxygen tension (PO2)-regulated red blood cell (RBC) capillary velocity has emerged recently as a new mechanism regulating cerebral capillary perfusion and measures RBC responses to local hypoxia. Such intrinsic RBC responses to PO2 changes may change distinctly under different pathological conditions and thus represent a new RBC-based approach for disease diagnosis. Indeed, our preliminary results showed that RBCs collected from ME/CFS patients exhibited impaired velocity in a microfluidic capillary in response to reduced PO2 and PO2-regulated RBC capillary velocity was improved significantly when patients received craniocervical instability surgery, strongly suggesting that PO2-regualted RBC capillary velocity may represent a new characteristic of ME/CFS that might be used to diagnose ME/CFS and measure ME/CFS progression. Here, we extend our preliminary study and propose an interdisciplinary approach combing microfluidics, machine learning and RBC cytokine assay to examine rigorously the accuracy of PO2-regulated RBC capillary velocity as a new laboratory test for ME/CFS and investigate mechanistically the roles of RBC cytokine signaling in ME/CFS. Aim 1 will measure PO2-regulated RBC capillary velocity using RBCs from 96 participants and compare the results of ME/CFS patients with age, gender and race-matched healthy controls. Furthermore, we will develop machine-learning algorithms to establish a diagnostic classifier to validate PO2-regulated RBC capillary velocity as a new laboratory test for ME/CFS and assess its feasibility to differentiate ME/CFS patients with different disease severity. Mechanistically, we will examine hemoglobin-band 3 interactions in RBCs from ME/CFS patients and examine their correlations with increased oxidative stress in ME/CFS. Aim 2 will quantify the cytokine profile in RBCs from ME/CFS patients and compare them with age, gender and race-matched healthy controls. Furthermore, we will alter the RBC cytokine profile and measure the corresponding changes of PO2-regulated RBC capillary velocity to examine whether RBC cytokine profile plays a role in the modulation of PO2-regulated RBC capillary velocity. These experiments will provide a previously unrecognized RBC cytokine signaling in ME/CFS and add new insights to the immune dysregulation in ME/CFS. Together, the proposed studies exploit new tools and technology to develop a new laboratory test for ME/CFS and reveal mechanistims underlying PO2-regulated RBC capillary velocity in ME/CFS, which we believe will directly improve the diagnosis and treatment of ME/CFS.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $182,069 )
2025	2025	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Allergy and Infectious Diseases Research	000	2	11/1/2024	NON-COMPETING CONTINUATION	$182,069
														Subtotal = $182,069

Issue Date FY: 2024 ( Subtotal = $224,955 )
2024	2024	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Allergy and Infectious Diseases Research	000	1	11/30/2023	NEW	$202,459
2024	2024	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Allergy and Infectious Diseases Research	001	1	9/11/2024	NEW	$22,496
														Subtotal = $224,955

Grand Total All Awards = $407,024

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Develop a novel red blood cell-based microfluidic approach to assess and diagnose ME/CFS

Award Number: R21AI175960

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2023

PERIOD OF PERFORMANCE END DATE: 10/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer